Blood disorders may be proving ground for gene-editing technique

Editing the human genome has been a stand-by in sci-fi movies for decades. But Crispr—the relatively easy and inexpensive editing technique, with emphasis on relatively—has led many to believe such a disease-curing technology is within reach.

To see Crispr's real abilities in solving otherwise difficult medical problems, scientists may need to look at blood disorders.

As the article in Wired says, "Plenty of gene-editing techniques have been attempted as therapies, but few have made significant impacts—especially when it comes to diseases as complex as cancer. A better place to start testing gene therapies is with inherited blood disorders, like sickle cell anemia and beta thalassemia."

Check out the full article below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”